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A B S T R A C T
Purpose: Ehlers–Danlos syndrome (EDS) comprises a variety of inherited connective tissue disorders that
have been described in association with various neurological features. Until now the neurological
symptoms have not been studied in detail; therefore, the aim of this review is to analyze the possible
association between EDS, epilepsy and periventricular heterotopia (PH).
Methods: We have carried out a critical review of all cases of epilepsy in EDS patients with and without
PH.
Results: Epilepsy is a frequent neurological manifestation of EDS; generally, it is characterized by focal
seizures with temporo-parieto-occipital auras and the most common EEG ﬁndings epileptiform
discharges and slow intermittent rhythm with delta–theta waves. Epilepsy in EDS patients is usually
responsive to common antiepileptic therapy; very few cases of drug resistant focal epilepsy requested
surgical treatment, with favorable results in terms of outcome. Epilepsy is the most common presenting
neurological manifestation associated with PH in EDS patients. Abnormal anatomic circuitries (including
heterotopic nodules) could generate epilepsy in patients with PH.
Conclusion: Among the principal neurological manifestations, epilepsy and PH have a considerable
importance and can inﬂuence the long-term evolution of these patients. We hypothesize that PH may
determine the epileptic manifestations in patients with EDS; much remains to be learnt about the
relationships between nodules and the epileptic manifestations in EDS syndrome.
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Ehlers–Danlos syndrome (EDS) includes a group of hereditary
connective tissue disorders (genetics defects affecting the bio-
synthesis and structure of collagen type I, III and V), mainly
characterized by joint hypermobility, skin fragility, hyperexten-
sibility and easy bruisability.1–7 It may also presents neurological
features such as disease of the cerebrovascular system, peripheral
neuropathy, plexopathy, chronic pain syndrome, spontaneous
intracranial hypotension, polymicrogyria, subependymal periven-
tricular heterotopias and epilepsy.8–13 The spectrum of severity of* Corresponding author at: Child Neurology, Headache Paediatric Center,
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights rethese manifestations is variable, ranging from very mild ﬁndings to
severe debilitating disorder.14
Some patients may develop different types of epileptic
conditions, i.e. generalized or partial seizures, with different EEG
abnormalities.13–16
In this review, we analyze the main types of epilepsy reported
in patients affected by EDS and the neurologic aspects of
periventricular heterotopia (PH).
2. Classiﬁcation
The current Villefranche Classiﬁcation of EDS (1997) recognizes
six subtypes based on phenotype, inheritance pattern and
underlying biochemical and molecular defects.2 The most common
subtypes of EDS are the classic, hypermobility and vascular
subtypes while kyphoscoliosis, arthrochalasis and dermatospar-
axis types represent very rare conditions.17 This classiﬁcation is
very important in terms of management and counseling to the
patients and their families.served.
Table 1
Ehlers–Danlos syndrome classiﬁcation.
EDS subtypes (old name) Inheritance Genetic defects Major symptoms
Classic (I/II) AD COL5A1, COL5A2, Skin hyperextensibility, widened atrophic scars
Joint hypermobility, muscle weakness, distal contractures
Hypermobility (III) AD Unknown Generalized hypermobility and subtle skin ﬁndings
Vascular (IV) AD COL3A1 Arterial rupture at a young age
Vascular-like AD COL1A1 Features of both classic and vascular type
Cardiac-valvular AR COL1A2 Mild skin, joint hypermobility, hypotonia, osteopenia (in childhood);
valve disease (in adulthood)
EDS with periventricular heterotopia X-linked recessive FLNA, ARFGEF2 Nodular brain heterotopia and classic EDS symptoms
Kyphoscoliosis (VIa) AR Lysyl-hydroxylase (PLOD1) Early progressive kyphoscoliosis
Muscolocontractural (VIb) AR CHST14 Craniofacial abnormalities, joint contracture, hypotonia,
gastrointestinal and genitourinary problems
Arthrocalasia (VIIa/VIIb) AD COL1A1, COL1A2 Congenital bilateral hip dislocation
Dermatosparaxis (VIIc) AR ADAMTS2 Sagging skin, eye lid edema, short stature and ﬁngers
Periodontal (VIII) AD 12p13 Severe early periodontitis
Spondylocheirodysplastic AR SLC39A13 Short stature and mild skeletal dysplasia
EDS-osteogenesis imperfecta AD COL1A1, COL1A2 Bone fragility and classic EDS symptoms
Brittle cornea syndrome AR ZNF469
PRDM5
Ocular fragility and keratoconus
Progeroid EDS AR B4GALT7 Wrinkled face, curly ﬁne hair, periodontitis
Tenascin X deﬁcient AR? TNXB Joint hypermobility, hyperextensible and sleeve-like character
to skin, marked bruising, normal scarring
FKBP14 related AR FKBP14 Marked kyphoscoliosis, hearing loss, myopathy, short stature,
joint hypermobility
Adapted from De Paepe and Malfait17 and from Karaa and Stoler.20
AD: autosomal dominant and AR: autosomal recessive.
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several new EDS variants called for an enrichment of the
classiﬁcation (Table 1) because EDS pathogenesis may be
inﬂuenced by genetic defects involving the biosynthesis of other
extracellular matrix molecules components and processes18–21;
furthermore, many patients cannot be categorized into a subtype
because clinical manifestations are ambiguous.
In Classic type of EDS, the mutations in type V collagen include
heterozygous nonsense, frameshift or splice-site mutations in
COL5A1; these mutations introduce a premature stopcodon elicit
nonsense-mediated decay of the mutant mRNA, and hence no
abnormal protein is produced. As such, the result is diminished
production of alpha1-chains of type V collagen.22,23
EDS hypermobility type (EDS-HT) is considered an autosomal
dominant trait with incomplete penetrance, variable expressivity
and inﬂuenced by sex; in contrast to the other EDS variants, the
genetic defect of this type is still unknown24; haploinsufﬁciency for
Tenascin-X was found in some patients affected by hypermobility
type of EDS (EDS-HT).25
EDS vascular type is an autosomal dominant disorder caused by
mutations in gene COL3A1 coding for type III procollagen
synthesis. The type III procollagen is predominantly distributed
in the skin and walls of blood vessels; mutations in gene COL3A1
may lead to spontaneous arterial, intestinal or uterine rupture,
with consequent premature death.
The EDS kyphoscoliotic type is an autosomal recessive disorder
caused by mutations of PLOD1 gene, that encodes lysyl hydroxy-
lase-1; this enzyme is involved in the formation of intermolecular
crosslinks that provide stability to the collagen ﬁbrils.17
Mutations in CHST14, encoding dermatan-4-sulfotransferase-1,
cause a deﬁciency of dermatan sulfate (DS) which results in
impaired decorin-mediated collagen ﬁbril assembly and tissue
fragility. This type of EDS is deﬁned musculocontractural.19,26,27
Mutations of this gene can be present also in patients with another
subtype called EDS VIB-brittle cornea syndrome: this autosomal
recessive condition, is also determined by ZNF469 gene and by
PRDM5 gene mutations.
EDS arthrocalasia type (formerly types arthrocalasia A and B),
an autosomal dominant form, is very rare: this type is caused by a
defective processing of type I collagen synthesis. EDS type
arthrocalasia A is determined by a disruption of procollagen chaina1(I), encoded by COL1A. EDS type arthrocalasia B is due to the
abnormality of a2(I), procollagen chain encoded by COL1A2, and
result in exon 6 skipping or genomic deletion of exon 6 COL1A2
gene.28–30
The dermatosparaxis type of EDS is very rare (only 10 or
11patients have been reported) autosomal recessive condition
caused by abnormalities in ADAMTS2, which encodes for an N-
proteinase involved in the ablation of N-propeptides whose
cleavage is essential for complete maturation of collagen I.24
There are many other subtypes that have recently been
identiﬁed that are caused by defects in non-collagenous genes
that are involved in extracellular matrix organization.
Four EDS variants (arthrocalasia, classic with vascular rupture,
cardiac-valvular, and EDS/osteogenesis imperfect overlap) are
caused by dominant or recessive mutations in genes (COL1A1 and
COL1A2) encoding the two chains of collagen type I with defect in
structural proteins of collagen I. The mutations in type I collagen
include missense mutations in COL1A1 that lead to the production
of a1(I) dimmers.
The genetic etiology of another rare form of EDS associated with
PH was established by recognition of the similarity of the
neurology features with that of PH due to FLNA mutations.31
Mutations conferring loss of function at the FLNA (encoding
Filamin A) locus lead to X-linked periventricular nodular hetero-
topia (XL-PH).32 To date, this is the only conﬁrmed X-linked form of
EDS. Recently, Reinstein et al.33 have suggested that there is little
molecular or clinical justiﬁcation for considering EDS-PH as a
separate entity from XL-PH, but instead they proposed that there is
a spectrum of vascular and connective tissues anomalies associat-
ed with this condition for which all individuals with loss-of-
function mutations in FLNA should be evaluated.
3. Clinical manifestations
EDS displays skin hyperextensibility and fragility, soft velvety
skin, delayed wound healing atrophic scarring, joints hyperlaxity,
dislocations, pain easy bruising, soft connective tissue fragility
with possible involvement internal organs.
The autosomal dominant classic type of EDS is diagnosed by the
presence of the three major criteria: joint hypermobility,
hyperextensible skin and widened atrophic scars. In the group
A. Verrotti et al. / Seizure 23 (2014) 819–824 821of minor criteria are included the following manifestations: muscle
hypotonia, velvety skin, easy bruising and the characteristic facial
features (epichanthic folds, dilated scars on the forehead, excess
skin over the eyelids).17
EDS hypermobility type (EDS-HT) is deﬁned by the association of
generalized joint hypermobility, widespread musculoskeletal pain
and skin features like extensibility and smooth and velvety skin.24
Vascular type of EDS is characterized by excessive bruising and
tendency to hematomas. The skin is not hyperextensible, but thin
and translucent. These patients have a characteristic facial
appearance, with a thin delicate nose, thin lips, prominent bones
and milder laxity involvement. Although EDS vascular type has less
striking clinical features, it is the most severe type. In fact, the
vascular complications affected medium and large arteries:
arterial rupture and dissections, aneurysmal degeneration or
intracavitary bleeding are important complications.34
EDS kyphoscoliotic type is an autosomal recessive disorder
characterized by early onset progressive kyphoscoliosis, severe
neonatal muscular hypotonia, hyperextensible and bruisable skin,
generalized joint hyperlaxity, osteopenia, scleral fragility and risk
for rupture of ocular globe.17,21
Arthrochalasis type is characterized by severe joint hypermo-
bility, skin hyperextensibility, bruisable skin, atrophic scars,
muscular hypotonia, osteopenia, kyphoscoliosis and tissue fragili-
ty. The characteristic sign of this EDS type is congenital bilateral
hip dislocation28 and, rarely, cardiac involvement.35
Dermatosparaxis type of EDS is characterized by pronounced
skin fragility and a redundant appearance of the skin.24
EDS cardiac-valvular type presents in childhood with mild skin
and joint hypermobility, osteopenia, muscular hypotonia and is
complicated in adulthood by severe cardiac valve insufﬁciency.
The rare form of EDS, called ‘‘Brittle Cornea Syndrome’’, is mainly
characterized by ocular fragility, blue sclera and keratoconus
(associated with skin and joint hypermobility and kyphoscoliosis).
The patients affected by the spondylocheirodysplastic form of
EDS show moderate short stature, skeletal dysplasia, hypermobili-
ty of the small joints, hyperextensible thin skin, easy bruising,
bluish sclera.17
In the EDS-PH, seizures constituting the most common clinical
manifestation; vascular dilatation (mainly the aorta), joint hyper-
mobility and variable skin ﬁndings are also associated anomalies.
Tenascin X-deﬁcient EDS is distinguished from classical EDS by
autosomal recessive inheritance, absence of abnormal scarring in
the presence of profound joint hypermobility, very hyperexten-
sible skin and striking bruising.36,37 The presence of signiﬁcant
hypermobility in heterozygous carriers of null mutations sug-
gested TNXB as a candidate gene in EDS type III, the hypermobile
type, but wider screening failed to document mutations at
sufﬁcient frequency to account for EDS type III.
Progerioid EDS type is a new subtype of EDS characterized by
wrinkled, loose skin on the face, curly ﬁne hair, scanty eyebrows
and eyelashes, in addition to the classical features of EDS.29
Periodontitis type of Ehlers–Danlos syndrome (EDS type VIII) is
distinguished from other subtypes of EDS by severe periodontitis
leading to premature loss of permanent teeth. The spectrum of skin
manifestations includes skin hyperextensibility, easy bruising,
pretibial discoloration, dystrophic scar formation. The skeletal
phenotypes include joint laxity and dislocations, Marfanoid
habitus, osteopenia, early-onset osteoarthritis, pectus deformity,
scoliosis and pes planus.33
4. EDS and epilepsy
EDS may be accompanied by congenital or acquired central
nervous system disorders and epilepsy.10 The frequency of the EDS
patients who suffer from epilepsy is not known.In literature, there are no data about a possible higher
prevalence of epilepsy in patients with EDS; probably, in patients
with EDS there is a higher prevalence of epilepsy: in fact, in some
patients a certain disruption in the link between the extracellular
matrix and cytoskeleton with consequent malformations of the
vessels and brain parenchyma can contribute to seizures;
moreover, it is probable that those patients with structural
abnormalities of central nervous system (such as PH) can suffer
from epilepsy.
We report and analyze all cases of epilepsy in EDS patients with
and without PH.
In most cases, epilepsy begins in childhood with focal seizures
(especially in temporal areas). The most common EEG ﬁndings
were interictal epileptiform discharges, slow intermittent rhythm
with delta–theta waves.
The ﬁrst EDS patient who presented epilepsy was described by
Herrero in 1972.9
Some years later, Cupo et al. described a female patient, 30
years old, with EDS and grand mal seizures beginning at the age 21
years; she presented cerebral heterotopias with peculiar vascular-
ization, that probably caused the seizure disorder. She died for
myocardial infarction (aneurysm of the sinuses of Valsalva).38
Thereafter, Pretorius in 1983 described a female, 22 years old,
affected by EDS type 1, presenting partial seizures that began
generalized.12
Another patient with generalized epilepsy was described by
Herrero in 1995: conventional antiepileptic drugs (AEDs) appeared
to be ineffective; however, the newer AEDs had a positive effect.9
Also another author10 reported cases with seizures onset in
childhood: these patients presented partial seizures except two
who suffered from grand mal.
In 2000, Echaniz–Laguna described two cases: one 29 years old
male patient had partial seizures that began at the age of 10 years;
EEG showed left fronto-central area sharp-wave discharges that
rapidly diffused over the two hemispheres, well controlled by
carbamazepine treatment. The other patient showed generalized
epilepsy, diffuse spike-waves at EEG and polymicrogyria; after
treatment with anterior callosotomy there was a reduction of
frequency and severity of seizures.39
Another important study40 reported 7 news epileptic patients;
all these patients showed bilateral nodular heterotopia (PNH)
suggesting an association between epilepsy and this cerebral
malformation.
Among the family studies, it is important to report the clinical
and genetic analysis of a Spanish family in which three women
suffered from EDS; a female patient had a history of spontaneous
luxation since childhood and complex partial epilepsy followed by
secondarily generalized tonic–clonic seizures since the age of 20
years. EEG showed temporal slow waves and MRI showed bilateral
PNH. Also her daughter, from the age of 14 years had recurrent
knee dislocations without seizures; her brain MRI revealed
bilateral PNH and mega cisterna magna. The third case was an
affected 19 years old woman (daughter of second patient) with a
history of recurrent patellar dislocation, joint hypermobility, soft
rubbery skin; at age of 18 years showed generalized epilepsy; she
had PNH and mega cisterna magna.15
Twenty-two EDS patients were reported in our review: 17/22
patients (77.3%) were female, 4/22 patients (18.2%) were male, in
one case (4.6%) was not reported the sex of the patient. Epilepsy
started in childhood in 8/22 patients (36.4%), after 9 years of age in
10/22 patients (45.5%), while in 4/22 cases (18.2%) was not
reported the age of epilepsy onset. The population consisted of the
following types of EDS: one patient (4.6%) was affected by EDS type
I, 3/22 patients (13.7%) by type III, 3/22 patients (13.7%) by type IV;
2/22 patients (9.1%) by type IX; in 2/22 cases (9.1%) were not sure
the type of EDS (in Table 1, the patient number 8 and the patient
Table 2
Pertinent data of the studies examined.
Case Reference Sex/age
(yr)
EDS
type
Age of onset
of epilepsy
Type of
seizures
EEG patterns Therapy Follow-up PH
1 Herrero, 1972 N.A. N.A. N.A. N.A. N.A. N.A. N.A. N.A.
2 Cupo, 1981 F, 30 N.A. 21 years Grand mal Right temporal focal seizures discharges N.A. Died for myocardial infarction
(aneurysm of the sinuses
of Valsalva)
Yes
3 Pretorius, 1983 F, 22 I 11 years Partial and
generalized
N.A. N.A. N.A. Ectopic gray
matter
4 Thomas, 1996 F, 24 N.A. 14 years Partial Isolated slow spike waves over the
left frontocentral area
Phenobarbital
150–200mg/day
Generalized szs when fenozolone
was added to antiepileptic therapy
Yes
5 Jacome, 1999 M, 36 IX (OHS) Childhood Partial Bilateral Theta slowing Carbamazepine Seizures free N.A.
6 Jacome, 1999 M, 29 IX (OHS) Childhood Partial Generalized sharp and slow
wave complexes of
frontal accentuation
Reduction of szs with
combination
of carbamazepine and
valproate
Pseudosz improved with
ﬂuoxetine and psychotherapy
N.A.
7 Jacome, 1999 F, 70 IV Grand mal
szs during
childhood
Partial 6-H posterior dominant rhythm.
Excessive intermixed
slow activity while awake;
generalized theta burst
Carbamazepine and
phenytoin.
Persistence of generalized
epilepsy
N.A.
8 Jacome, 1999 F, 28 III (?) Grand mal
in childhood
Partial Generalized sharp theta discharges AEds Poor control N.A.
9 Jacome, 1999 M, 69 IV 46 years Generalized
and partial
Mild slowing of background in theta range Valproate and phenytoin N.A. N.A.
10 Jacome, 1999 F, 35 IV N.A. Partial Normal Valproate Szs free N.A.
11 Jacome, 1999 F, 68 III or IV (?) N.A. Generalized Normal Phenobarbital Szs free N.A.
12 Echaniz-Laguna,
2000
M, 29 N.A. 10 years Partial with
secondary
generalization
Left fronto-central area sharp-wave discharges
that rapidly diffused over the two hemisphere
Phenobarbital, valproate
carbamazepine
Szs free N.A.
13 Echaniz-Laguna,
2000
F, 22 III Childhood Generalized szs Generalized spikes AEDs and anterior
callosotomy
Reduction of frequency and
severity of seizures after
callosotomy
N.A.
14 Sheen, 2005 F, 7 N.A. 6 Single seizure N.A. N.A. N.A. Yes
15 Sheen, 2005 F, 24 N.A. 22 NA N.A. N.A. N.A. Yes
16 Sheen, 2005 F, 25 N.A. 17 Generalized
(catamenial)
Excessive slow wave activity N.A. N.A. Yes
17 Sheen, 2005 F, 53 N.A. Epilepsy since
childhood
N.A. N.A. N.A. N.A. Yes
18 Sheen, 2005 F, 18 N.A. 4 Partial Multifocal sharp and spike waves N.A. N.A. Yes
19 Sheen, 2005 F, 29 N.A. 14 Generalized N.A. N.A. N.A. Yes
20 Sheen, 2005 F, 15 N.A. N.A. Focal N.A. N.A. N.A. Yes
21 Gomez-Garre,
2006
F, 68 III 20 Partial szs with
secondary
generalization
Temporal slow waves N.A. N.A. Yes
22 Gomez-Garre,
2006
F, 19 III 18 Generalized N.A. N.A. N.A. Yes
Abbreviations: SZS: seizure; PH: periventricular heterotopia; OHS: occipital horn syndrome; AEDs: antiepileptic drugs; NA: not available.
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not mentioned. The large majority of patients presented partial
seizures (8/22 patients, 36.4%), 5/22 (22.8%) generalized epilepsy,
2/22 (9.1%) had generalized and partial seizures, one patient (4.6%)
presented grand mal; in two cases (9.1%) partial seizures with
secondary generalization were reported and in 4 cases (18.2%) the
characteristics of the epilepsy were missing. Four out of 22 patients
received antiepileptic drug (AED) monotherapy while 6 patients
(27.3%) were treated with polytherapy; in the other cases the
treatment was not reported. At last follow-up, only 4 patients were
seizure-free (the time of the follow-up is unknown).
5. EDS and periventricular heterotopia
PH includes a group of neuronal migration disorders charac-
terized by clinical and genetic variability. Three main groups are
described: PNH, subcortical heterotopia and marginal glioneural
heterotopia.41–43 Disorders affecting neuronal migration are
characterized by abnormal neuronal positioning. When migration
is impaired during later cortical development, abnormal cell
position is more likely to be restricted to the cortex.44–47
The association of EDS with PH is difﬁcult to explain. A disruption
in the link between the extracellular matrix and cytoskeleton could
cause an aberration in cellular migration during development with
possible congenital malformations of the vessels and the brain
parenchyma, including cortical dysgenesis.40,48,49
EDS is considered a disorder of the extracellular matrix related
with a disruption in glycoproteins, involving collagen or proteo-
glycans or other extracellular matrix proteins like Tenascin-
X.36,50,51 Cells join to the extracellular matrix by integrins, whose
intracellular portion binds to the actin ﬁlaments of the cytoskele-
ton. Filamin A (FLNA) links the beta-integrin cell adhesion
receptors, but does not alter the formation of these focal adhesion
sites and the extracellular matrix assembly.52–56 Otherwise, FLNA
mutations could decrease the connection of the cells to the
extracellular matrix or compromise regulation to the cytoskeleton
through the FLNA binding to integrins proteins.49,57 Furthermore, a
relationship between FLNA and collagen can have a role in the
mechanism of platelet aggregation; in fact, mutations in the FLNA
and in COL3A1 gene (vascular type of EDS) are both known to
determine excessive bleeding, probably due to vascular fragility
and platelet dysfunction49,58; mutations in FLNA can cause classic
bilateral PNH,59–64,32,65 and the inheritance can be X-linked
dominant (mutations in the Filamin A gene) or autosomal recessive
(mutations in ARFGEF2 gene).40 This last mutation has been
associated to PNH but in patients without EDS.
Most cases of patients with PH present epilepsy66–71; the type
of seizures is variable, even if majority of patients have partial
attacks with temporo-parieto-occipital aura, and the severity may
range from mild (with remission without anticonvulsant therapy)
to intractable epilepsy. Age of onset is also variable from ﬁrst year
of life to adolescence.47,72–76 No correlation has been found
between the extent and severity of the PH and frequency of
seizures. It has been suggested that onset of seizures can begin
simultaneously from periventricular heterotopic cortex and from
distantly located cortical areas. In Table 2 we report the data of the
EDS patients affected by epilepsy and PH.
Actually, no guidelines are described for the treatment and
management of PH and its complications. In most cases, antie-
pileptic drugs are used to control seizures with good results.72,76
For intractable focal seizures, surgical resection can be request.
6. Conclusions
EDS may affect central nervous system although not many cases
of patients affected by EDS and epilepsy are reported; frequently,they show PH. It is possible that the nodules, the main lesions of
PH, can determine the epileptic manifestations present in patients
with EDS. A careful evaluation of patients may reveal asymptom-
atic and unrecognized abnormalities, which offer better explana-
tions for the symptoms and must be considered for the prognosis.
EEG recording, neuroimaging and neuropsychological tests can
help to deﬁne diagnosis and to have a better care for people affected
by EDS and epilepsy. It is important to reach a clearer understanding
of the possible mechanisms underlying epileptic disorder, to
improve therapy and long-term outcome of these patients.
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